Abstract：
Glucagon-like peptide 1 (GLP-1) receptor agonists are widely used for glycemic control in patients with diabetes mellitus (DM) and are primarily indicated for type 2 diabetes mellitus (T2DM). GLP-1 receptor agonists have also been shown to have neuroprotective and antidepressant properties. Replicated evidence suggests that individuals with DM are significantly more likely to develop depression. Herein, we aim to investigate whether GLP-1 receptor agonists can be used prophylactically on patients with DM to lower the risk of incident depression. We conducted a systematic search for English-language articles published on the PubMed/MEDLINE, Scopus, Embase, APA, PsycInfo, Ovid and Google Scholar databases from inception to June 6, 2022. Four retrospective observational studies were identified that evaluated the neuroprotective effects of GLP-1 receptor agonists on incident depression in patients with DM. We found mixed results with regards to lowering the risk of incident depression, with two studies demonstrating a significant reduction in risk and two studies showing no such effect. A single study found that dulaglutide may lower susceptibility to depression. Our results were limited by high interstudy heterogeneity, paucity of literature, and lack of controlled trials. While we did not find evidence of GLP-1 receptor agonists significantly lowering risk of incident depression in patients with DM, promising neuroprotective data presented in two of the included papers, specifically on dulaglutide where information is scarce, provide the impetus for further investigation. Future research should focus on better elucidating the neuroprotective potential of different classes and doses of GLP-1 receptor agonists using controlled trials.
摘要：
胰高血糖素样肽1（GLP-1）受体激动剂广泛用于糖尿病（DM）患者的血糖控制，主要用于2型糖尿病（T2DM）。GLP-1受体激动剂也已显示具有神经保护和抗抑郁性质。重复的证据表明，患有DM的个体更有可能患上抑郁症。在这里，我们的目的是研究GLP-1受体激动剂是否可以预防性用于DM患者,以降低抑郁发生率的风险.我们对PubMed/MEDLINE上发表的英语文章进行了系统的搜索，Scopus,Embase,APA,PsycInfo,Ovid和GoogleScholar数据库从成立到2022年6月6日。确定了四项回顾性观察性研究，评估了GLP-1受体激动剂对DM患者偶发抑郁症的神经保护作用。我们发现在降低偶发抑郁症的风险方面的结果好坏参半，两项研究表明风险显着降低，两项研究表明没有这种效果。一项研究发现，杜拉鲁肽可能会降低抑郁症的易感性。我们的结果受到研究间高度异质性的限制，文学的匮乏，缺乏对照试验。虽然我们没有发现GLP-1受体激动剂显著降低DM患者发生抑郁的风险的证据，在其中两篇论文中提出了有希望的神经保护数据，特别是在信息稀缺的杜拉鲁肽上，为进一步调查提供动力。未来的研究应该集中在使用对照试验更好地阐明不同类别和剂量的GLP-1受体激动剂的神经保护潜力。
